In addition, aldometanib did not promote the infiltration of HCC by Th17 cells, which are known to contribute to the activation of CD8+ T cells in tumor tissues (Supplementary information, Fig. S9j). This evidence concerns the gene CD8A and hepatocellular carcinoma.